Rheumatology, Saveetha Medical College Hospital, Chennai, India.
Rheumatology, Gleneagles Global and Vijaya hospitals, Chennai, India.
Int J Rheum Dis. 2022 Sep;25(9):1046-1052. doi: 10.1111/1756-185X.14378. Epub 2022 Jun 30.
This survey was conducted to evaluate COVID-19 vaccination status in patients with autoimmune rheumatic diseases (AIRDs). Our objectives were to study vaccine hesitancy, adverse effects, breakthrough infections and flare of underlying disease in this population subgroup.
This was a multi-center, cross-sectional, interview-based survey done at 6 tertiary care centers across Tamil Nadu, in the southern part of India from September 15, 2021 to October 14, 2021. The survey questionnaire was filled up by AIRD patients attending their clinics. The survey questionnaire comprised a set of 14 questions, distributed between patient characteristics, vaccines taken, their characteristics and COVID-19 infection.
There were 2092 participants, with a mean age of 47.5 ± 13.17 years. Among them, 1293 (61.81%) were vaccinated, of which 837 (64.73%) were fully vaccinated. Two-thirds of our subjects were vaccinated with ChAdOx1 nCov-19 (COVISHIELD) (77.64%) and 21.57% with BBV 152 (COVAXIN). Age, gender, education and comorbidities had no association with vaccine hesitancy. The commonest (421; 52.69%) reason for vaccine hesitancy was fear of side effects. The incidence (n = 72) of breakthrough infections was similar in both the vaccine groups, of which 58 (80.55%) were partially vaccinated and 14 (19.44%) were fully vaccinated. Thirty-two patients had a flare of pre-existing rheumatic disease.
ChAdOx1 nCov-19 and BBV 152 were found to be safe in patients with rheumatic diseases. Fear of side effects was the major cause of vaccine hesitancy. All adverse effects were minor and self-limiting. Breakthrough infections and disease flares occurred only in a small subset of our cohort.
本调查旨在评估自身免疫性风湿病（AIRD）患者的 COVID-19 疫苗接种状况。我们的目标是研究该人群亚组中的疫苗犹豫、不良反应、突破性感染和基础疾病加重。
这是一项多中心、横断面、基于访谈的调查，于 2021 年 9 月 15 日至 10 月 14 日在印度南部泰米尔纳德邦的 6 家三级护理中心进行。AIRD 患者在就诊时填写调查问卷调查表。调查问卷调查表由一组 14 个问题组成，分布在患者特征、接种的疫苗及其特征和 COVID-19 感染之间。
共有 2092 名参与者，平均年龄为 47.5±13.17 岁。其中，1293 人（61.81%）已接种疫苗，其中 837 人（64.73%）已完全接种疫苗。我们的研究对象中有三分之二（77.64%）接种了 ChAdOx1 nCov-19（COVISHIELD），21.57%（21.57%）接种了 BBV 152（COVAXIN）。年龄、性别、教育程度和合并症与疫苗犹豫无关。最常见（421；52.69%）的疫苗犹豫原因是担心副作用。在两组疫苗中，突破性感染的发生率（n=72）相似，其中 58 例（80.55%）为部分接种，14 例（19.44%）为完全接种。32 例患者出现原有风湿病加重。
ChAdOx1 nCov-19 和 BBV 152 被发现可安全用于风湿病患者。对副作用的恐惧是疫苗犹豫的主要原因。所有不良反应均为轻微且自限性的。突破性感染和疾病加重仅发生在我们队列的一小部分患者中。
